Product
Cusatuzumab
Aliases
ARGX-110, JNJ-74494550
4 clinical trials
3 indications
Indication
LeukemiaIndication
myeloidIndication
AcuteClinical trial
A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Candidates for Intensive ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2023-08-15
Clinical trial
A Phase 1 Study of Cusatuzumab Plus Azacitidine in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive TreatmentStatus: Completed, Estimated PCD: 2021-07-19
Clinical trial
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2024-05-15
Clinical trial
Multicenter, Open-label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive TherapyStatus: Not yet recruiting, Estimated PCD: 2027-01-01